Voglibose, an N-substituted derivative of valiolamine, can inhibit α-glucosidase and be used to treat hyperglycemia and its concomitant diseases.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | D-Glucose and insulin levels of plasma are usually high in diabetics especially after food ingestion, and reducing intestinal carbohydrate absorption, such as monosaccharides, which are hydrolyzed by α-glucosidase, is one way to control disorders of carbohydrate metabolism. Voglibose, a α-glucosidase inhibitor, delays the digestion and absorption of carbohydrates and is the aid in the treatment of diabetes[3]. In the case of postprandial glucose excursion, oral administration of voglibose (0.2 mg/kg) reduced the carbohydrate-induced increase in blood glucose without causing sustained hypoglycemia in both normal and neonatal streptozotocin-induced diabetic rats[4]. In prediabetic db/db mice, voglibose decreased the average food consumption by 37% compared with vehicle-treated mice. Furthermore, voglibose treatment increased GLP-1 (glucagon-like peptide-1) secretion, while it decreased plasma glucose-dependent insulinotropic polypeptide (GIP)[5]. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT02456428 | - | Completed | - | Canada, Quebec ... 展开 >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 收起 << | |
NCT02476760 | - | Completed | - | Canada, Quebec ... 展开 >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 收起 << | |
NCT02685410 | HIV Prevention ... 展开 >> STI Prevention 收起 << | Not Applicable | Completed | - | United States, Connecticut ... 展开 >> Yale New Haven Hospital New haven, Connecticut, United States, 06510 收起 << |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.74mL 0.75mL 0.37mL |
18.71mL 3.74mL 1.87mL |
37.41mL 7.48mL 3.74mL |
CAS号 | 83480-29-9 |
分子式 | C10H21NO7 |
分子量 | 267.276 |
别名 | AO-128 |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Keep in dark place,Sealed in dry,Store in freezer, under -20°C |
溶解度 |
DMSO: 105 mg/mL(392.85 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO H2O: 250 mg/mL(935.36 mM),配合低频超声助溶 |
动物实验配方 |